ACETO Corporation Schedules Third Quarter Fiscal 2017 Financial Results News Release and Conference Call
April 21 2017 - 8:00AM
ACETO Corporation (NASDAQ:ACET), an international company engaged
in the development, marketing, sales and distribution of Human
Health products, Pharmaceutical Ingredients and Performance
Chemicals, will issue its financial results of operations for the
third quarter of fiscal 2017 ended March 31, 2017 after the stock
market close on Thursday, May 4, 2017.
Management will host a conference call to
discuss the operating and financial results at 9:00am ET on Friday,
May 5, 2017. To participate in the conference call, please
dial 877-317-6789 or 412-317-6789 approximately 10 minutes prior to
the call. Please reference conference ID #
10105981.
A live webcast of the conference call will be
available in the Investor Relations section of the Company’s
website, www.aceto.com. Please access the website 15 minutes
prior to the start of the call to download and install any
necessary audio software.
A telephone replay of the conference call will
be available from 11:00 a.m. ET on May 5, 2017 until 11:59 p.m. ET
on May 12, 2017 and may be accessed by calling (888) 843-7419 and
reference conference ID # 10105981. An archived replay of the
conference call will also be available in the investor relations
section of the Company’s website.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with
offices and operations in 10 countries, is engaged in the
development, marketing, sale and distribution of Human Health
products (finished dosage form generics and nutraceuticals),
Pharmaceutical Ingredients (pharmaceutical intermediates and active
pharmaceutical ingredients) and Performance Chemicals (specialty
chemicals and agricultural protection products).
FORWARD LOOKING STATEMENTS
This news release contains forward-looking
statements as that term is defined in the federal securities
laws. The events described in forward-looking statements
contained in this news release may not occur. Generally,
these statements relate to our business plans or strategies,
projected or anticipated benefits or other consequences of ACETO’s
plans or strategies, financing plans, projected or anticipated
benefits from acquisitions that ACETO may make, or a projection
involving anticipated revenues, earnings or other aspects of
ACETO’s operating results or financial position, and the outcome of
any contingencies. Any such forward-looking statements are
based on current expectations, estimates and projections of
management. ACETO intends for these forward-looking statements to
be covered by the safe-harbor provisions for forward-looking
statements. Words such as "may," "will," "expect," "believe,"
"anticipate," "project," "plan," "intend," "estimate," and
"continue," and their opposites and similar expressions are
intended to identify forward-looking statements. The
forward-looking statements contained in this press release include,
but are not limited to, statements regarding the Company’s
strategic initiatives including selling finished dosage form
generic drugs, and statements regarding the prospects for long-term
growth. ACETO cautions you that these statements are
not guarantees of future performance or events and are subject to a
number of uncertainties, risks and other influences, many of which
are beyond ACETO’s control, which may influence the accuracy of the
statements and the projections upon which the statements are
based. Factors that could cause actual results to differ
materially from those set forth or implied by any forward-looking
statement include, but are not limited to, risks and uncertainties
discussed in ACETO’s reports filed with the Securities and Exchange
Commission, including, but not limited to, ACETO’s Annual Report on
Form 10-K for the fiscal year ended June 30, 2016 and other
filings. Copies of these filings are available at www.sec.gov.
Any one or more of these uncertainties, risks
and other influences could materially affect ACETO’s results of
operations and whether forward-looking statements made by ACETO
ultimately prove to be accurate. In addition, periodic high-margin
product sales may have a positive material financial impact in a
given quarter that may be non-recurring in future quarters, thereby
rendering one quarter's performance not useful as a predictor of
future quarters' results. ACETO’s actual results, performance and
achievements could differ materially from those expressed or
implied in these forward-looking statements. ACETO undertakes no
obligation to publicly update or revise any forward-looking
statements, whether from new information, future events or
otherwise.
Investor Relations Contact:
LHA
Jody Burfening
jburfening@lhai.com
(212) 838-3777